Anzeige
Mehr »
Donnerstag, 24.07.2025 - Börsentäglich über 12.000 News
Neubewertung voraus? Wird die Aktivierung der EU-Lizenz zum Kurs-Katalysator für die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2GA | ISIN: BMG0360L1349 | Ticker-Symbol:
NASDAQ
19.12.24 | 21:44
0,300 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALTAMIRA THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
ALTAMIRA THERAPEUTICS LTD 5-Tage-Chart

Aktuelle News zur ALTAMIRA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.07.Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Intranasal Betahistine96HAMILTON, BM / ACCESS Newswire / July 15, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing therapeutics that address important unmet medical...
► Artikel lesen
17.06.NSE - Altamira Therapeutics Ltd. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities2
11.06.Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer1
ALTAMIRA THERAPEUTICS Aktie jetzt für 0€ handeln
11.06.Delisting of Securities of Blue Star Foods Corp.; Altamira Therapeutics Ltd.; Evergreen Corporation; Fresh2 Group Limited; Coliseum Acquisition Corp.; The Real Good Food Company, Inc.; Mynaric AG; byNordic Acquisition Corporation; ...515NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Blue Star Foods Corp. Blue Star Foods Corp.'s stock was suspended on December...
► Artikel lesen
09.05.Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer1
30.04.Altamira Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers5
30.04.Altamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results235Hamilton, Bermuda, April 30, 2025 (GLOBE NEWSWIRE) -- Management to host conference call today, April 30, at 8:00 a.m. EDTRNA delivery business progressing with platform development, new applications...
► Artikel lesen
30.04.Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer1
25.04.Altamira Therapeutics Ltd: Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 20251
04.04.Altamira Therapeutics Ltd. - S-8, Securities to be offered to employees in employee benefit plans2
10.03.Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer3
07.03.Altamira Therapeutics Ltd: Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent2
22.01.Altamira Therapeutics Ltd: Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies209Hamilton, Bermuda, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Exploring use of Altamira's RNA nanoparticles in conjunction with radiopharmaceutical cancer treatment Project collaboration partner will have...
► Artikel lesen
31.12.24Altamira Therapeutics Ltd: Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA231Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira's platform for extrahepatic RNA deliveryCircular mRNA significantly increasing protein expression...
► Artikel lesen
20.12.24Altamira Therapeutics Ltd: Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets433HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol "CYTOF"No reverse stock split planned Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:...
► Artikel lesen
04.10.24Altamira Therapeutics Ltd: Altamira Therapeutics Provides Update on Nasdaq Listing333Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the...
► Artikel lesen
24.09.24Altamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results241Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new...
► Artikel lesen
16.09.24Altamira Therapeutics Ltd: Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia184Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing...
► Artikel lesen
23.08.24Altamira Therapeutics Ltd: Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark147Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024Exclusive distribution agreement extended to also include Sweden and Denmark...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1